A Robust Optimization Approach to Cancer Treatment under Toxicity Uncertainty.

about

A Robust Optimization Approach to Cancer Treatment under Toxicity Uncertainty.

Item

http://www.wikidata.org/entity/Q49979322

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

A Robust Optimization Approach to Cancer Treatment under Toxicity Uncertainty.

@en

A Robust Optimization Approach to Cancer Treatment under Toxicity Uncertainty.

@nl

type

Item

label

A Robust Optimization Approach to Cancer Treatment under Toxicity Uncertainty.

@en

A Robust Optimization Approach to Cancer Treatment under Toxicity Uncertainty.

@nl

prefLabel

A Robust Optimization Approach to Cancer Treatment under Toxicity Uncertainty.

@en

A Robust Optimization Approach to Cancer Treatment under Toxicity Uncertainty.

@nl

P1476

A Robust Optimization Approach to Cancer Treatment under Toxicity Uncertainty.

@en

P2093

Hamidreza Badri

http://www.w3.org/2001/XMLSchema#string

Junfeng Zhu

http://www.w3.org/2001/XMLSchema#string

Kevin Leder

http://www.w3.org/2001/XMLSchema#string

P2860

Evolutionary dynamics of cancer in response to targeted combination therapy

Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

Evolution of acquired resistance to anti-cancer therapy.

Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease.

P304

297-331

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/978-1-4939-7493-1_15

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

1711

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29344896

http://www.w3.org/2001/XMLSchema#string